TY - JOUR AU - Doğan, Ali AU - Demircioğlu, Sinan PY - 2019/08/21 Y2 - 2024/03/29 TI - Assessment of the Neutrophil-Lymphocyte Ratio in Classic Hodgkin Lymphoma Patients: Classic Hodgkin Lymphoma JF - Pakistan Journal of Medical Sciences JA - Pak J Med Sci VL - 35 IS - 5 SE - Original Articles DO - 10.12669/pjms.35.5.601 UR - https://www.pjms.org.pk/index.php/pjms/article/view/601 SP - AB - Background and Objective: Besides known risk scoring systems, studies have recently been conducted in relation to NLR to estimate the prognosis of HL. Some studies found a relationship of NLR with PFS and OS. Our objective was to investigate whether NLR, as an inexpensive and easily accessible test, is a prognostic marker for cHL, as in several previous studies.Methods: The study included 232 patients in the age range of 18 to 88 years who were diagnosed with classic Hodgkin Lymphoma and received ABVD chemotherapy and/or radiotherapy at Van Yuzuncu Yil University Hematology Clinic from 2000-2018. Analyses were conducted on the disease stage, risk scores, treatment responses and relapse statuses at the time of diagnosis based on the patients’ NLR values at the time of diagnosis.Results: The mean age of the patients was 39.27 ± 15.90, while 38.8% were female and 61.2% were male. The NLR value at the time of diagnosis was significantly related to stage (p:0.013), early-stage risk score (p:0.022) and treatment response (p:0.032). The cutoff value of NLR was found as 4.23. The Hb value at the time of diagnosis was significantly related to stage (p:0.00), early-stage risk score (p:0.007), treatment response (p:0.006) and the latest status of patients (p:0.005).Conclusion: High NLR values were found to be significantly related to disease stage, early-stage risk scoring and response to the treatment. These findings need to be supported by prospective studies with larger samples for these data to be used prognostic scores.doi: https://doi.org/10.12669/pjms.35.5.601How to cite this:Dogan A, Demircioglu S. Assessment of the Neutrophil-Lymphocyte Ratio in Classic Hodgkin Lymphoma Patients. Pak J Med Sci. 2019;35(5):1270-1275. doi: https://doi.org/10.12669/pjms.35.5.601This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ER -